Actinium Pharmaceuticals (ATNM) 10-K2020 FY Annual report

Filed: 31 Mar 21, 5:00pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accessibility, aforementioned, allegedly, Allergan, altogether, analytical, anesthesiologist, appeal, assemble, automatically, auxiliary, avoid, beneficiary, Biden, bound, broadly, Circuit, circumvent, clearance, closer, complaint, complement, composing, conceal, concealing, Congressional, constrain, contemplated, coping, corruption, counterparty, cyber, cybersecurity, cytometry, deadly, debilitating, defective, developmental, diminish, diminished, disability, dispersed, district, DLBCL, dosage, Dosimetry, downgrade, drawn, ease, EFS, element, embezzling, England, ethically, expenditure, falsifying, FBR, formulary, forum, fourteen, gathered, harbor, hereto, hoc, homeostatic, hypothesized, immunology, inaccurate, indefinite, internet, JonesTrading, Justice, justify, kind, learning, Loughlin, malware, marker, Midostaurin, misappropriation, moiety, move, NIH, nominee, nonclinical, nurse, obstructing, occupation, offense, panel, passed, PDUFA, pediatric, percentile, PFO, phishing, PHSA, political, PR, practitioner, precautionary, predetermined, preempted, preliminarily, progenitor, promptly, properly, proportional, qui, radiochemistry, rank, readability, rebate, recommence, recovered, relaxation, relaxed, remanded, resubmit, resubmitted, resurgence, retroactively, Riley, risky, safeguarding, sampling, satisfactorily, satisfactory, scrutiny, se, short, social, solution, Sorafenib, speculative, speed, stealing, stricter, suboptimal, subpopulation, substantive, Subtopic, sue, SUPPLEMENTARY, tam, terrorist, theft, Thirteen, tracking, transmit, transparency, trend, Trump, unblinded, unclear, unconstitutional, undertaken, unemployment, unnoticed, unregistered, upgraded, user, vaccine, vendor, welfare, whistleblower, worsening

Removed: ACA, add, affiliated, Affordability, assert, attend, bid, CFO, challenge, clarify, classification, Codification, constitutionality, dated, decreased, divisional, exempt, explore, Goodwin, improvement, Kapur, LEAP, Medpace, MMA, Modernization, monotherapy, monthly, originally, overturn, penny, Pharmaceutica, poorer, pose, PPACA, Ray, reclassified, resell, resigned, salesperson, showing, Sr, standardized, teaching, tenant, tenure, tolerated, upheld, USA

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ATNM similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER, PURSUANT TO

18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Actinium Pharmaceuticals, Inc. a Delaware corporation (the “Company”), on Form 10-K for the period ended December 31, 2020 as filed with the Securities and Exchange Commission (the “Report”), I, Sandesh Seth, Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350), that to my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 31, 2021	By:	/s/ Sandesh Seth
		Sandesh Seth
		Chairman and Chief Executive Officer
		(Duly Authorized Officer, Principal Executive Officer)